Epigenetics and Disease

Pharmaceutical Opportunities

Nonfiction, Health & Well Being, Medical, Medical Science, Genetics
Cover of the book Epigenetics and Disease by , Springer Basel
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783764389895
Publisher: Springer Basel Publication: October 17, 2010
Imprint: Springer Language: English
Author:
ISBN: 9783764389895
Publisher: Springer Basel
Publication: October 17, 2010
Imprint: Springer
Language: English

Epigenetics has emerged recently as an important area of molecular biological studies. Epigenetic modifications lead to potentially heritable but reversible alterations in the expression of genes that determine cell fate. Epigenetic misregulation is thus often linked to degenerative diseases, cancer and neuronal disorders. Recent biomedical interest in this regulatory system stems from the fact that epigenetic, in contrast to genetic, alterations are in principle amenable to pharmacological intervention. A few epigenetically active drugs, for example histone deacetylase inhibitors (HDACi) and DNA methyltransferase (DNMT) inhibitors, have been approved by FDA for treatment of cancers such as CTCL, MDS, and AML. This volume explores the scientific background for clinical applications of epigenetically active drugs. Included are descriptions of epigenetic controls over gene expression, the post-transcriptional silencing of genes by RNA interference (RNAi) and microRNAs, as well as new findings from stem cell research which are relevant to pharmacological applications.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Epigenetics has emerged recently as an important area of molecular biological studies. Epigenetic modifications lead to potentially heritable but reversible alterations in the expression of genes that determine cell fate. Epigenetic misregulation is thus often linked to degenerative diseases, cancer and neuronal disorders. Recent biomedical interest in this regulatory system stems from the fact that epigenetic, in contrast to genetic, alterations are in principle amenable to pharmacological intervention. A few epigenetically active drugs, for example histone deacetylase inhibitors (HDACi) and DNA methyltransferase (DNMT) inhibitors, have been approved by FDA for treatment of cancers such as CTCL, MDS, and AML. This volume explores the scientific background for clinical applications of epigenetically active drugs. Included are descriptions of epigenetic controls over gene expression, the post-transcriptional silencing of genes by RNA interference (RNAi) and microRNAs, as well as new findings from stem cell research which are relevant to pharmacological applications.

More books from Springer Basel

Cover of the book Berichte zu Pflanzenschutzmitteln 2011 by
Cover of the book Around and Beyond the Square of Opposition by
Cover of the book The Power of the Terroir: the Case Study of Prosecco Wine by
Cover of the book Galanin by
Cover of the book Control and Optimization with PDE Constraints by
Cover of the book Mathematicians in Bologna 1861–1960 by
Cover of the book Fractal Symmetry of Protein Exterior by
Cover of the book A Comprehensive Treatment of q-Calculus by
Cover of the book Tamoxifen by
Cover of the book Infection, Immune Homeostasis and Immune Privilege by
Cover of the book T Lymphocytes as Tools in Diagnostics and Immunotoxicology by
Cover of the book Fluid-Structure Interaction and Biomedical Applications by
Cover of the book Alpine Treelines by
Cover of the book Proteases and Their Receptors in Inflammation by
Cover of the book Influenza Virus Sialidase - A Drug Discovery Target by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy